We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00800241
First Posted: December 2, 2008
Last Update Posted: December 3, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to determine the incidence of misuse, i.e., over-use and under-use, of Budesonide/formoterol for maintenance and reliever therapy in usual-care setting.

Condition
Asthma

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Budesonide/Formoterol for Maintenance and Reliever Therapy: A Medication Use Evaluation Among Persistent Asthma Patients in General Practice in Thailand

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number of budesonide/formoterol use per patient [ Time Frame: On the survey date ]

Estimated Enrollment: 1020
Study Start Date: May 2009
Study Completion Date: November 2009
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient aged 12 years or older who established persistent asthma and currently treated with Symbicort SMART for 3 months or longer.
Criteria

Inclusion Criteria:

  • Established persistent asthma
  • Currently treated with Symbicort SMART for 3 months or longer

Exclusion Criteria:

  • currently participating or have participated in a study with an investigational compound within the last 30 days
  • current diagnosis of chronic obstructive pulmonary disease (COPD)
  • smoked more than 10 pack-year
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00800241


Locations
Thailand
Research Site
Buriram, Thailand
Research Site
Chanthaburi, Thailand
Research Site
Chiang Mai, Thailand
Research Site
Mahasarakham, Thailand
Research Site
Nakhon Phanom, Thailand
Research Site
Nakhon Srithammarat, Thailand
Research Site
Nakhonpathom, Thailand
Research Site
Phattalung, Thailand
Research Site
Phitsanulok, Thailand
Research Site
Rayong, Thailand
Research Site
Roi Et, Thailand
Research Site
Samutsakhon, Thailand
Research Site
Surat Thani, Thailand
Research Site
Trang, Thailand
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Bandit Thinkhamrop, PhD. Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen University
Principal Investigator: Watchara Boonsawat, MD, PhD Department of Medicine, Faculty of Medicine, Khon Kaen University
  More Information

Responsible Party: Thanu Komolsai, MD, Medical Advisor, AstraZeneca (Thailand) Ltd.
ClinicalTrials.gov Identifier: NCT00800241     History of Changes
Other Study ID Numbers: NIS-RTH-SYM-2008/1
First Submitted: December 1, 2008
First Posted: December 2, 2008
Last Update Posted: December 3, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
Asthma
Symbicort SMART
Thai patient eligibility
Persistent asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Formoterol Fumarate
Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists